Biotech Values

[jq1234]

But what makes it unusual and complex is that he is proposing a dual MOA - both an anti-angiogenic initial action and a subsequent immune action.

There is no way of knowing if dual action actually occurred in human trials. One way to look at is via adverse event to see if they show up. I haven't seen much indication from adverse events indicating either anti-angiogenic activity or immune response.